Literature DB >> 26180727

Obesity-induced Lymphedema Nonreversible following Massive Weight Loss.

Arin K Greene1, Frederick D Grant1, Reid A Maclellan1.   

Abstract

Lymphedema is the progressive enlargement of tissue due to inadequate lymphatic function. Obesity-induced lymphedema of the lower extremities can occur once a patient's body mass index (BMI) exceeds 50. We report our first patient with obesity-induced lower extremity lymphedema who was followed prospectively before and after weight loss. A 46-year-old woman with a BMI of 80 presented to our Lymphedema Program complaining of bilateral lower extremity swelling. Lymphoscintigraphy showed impaired lymphatic drainage of both lower extremities consistent with lymphedema. She was referred to a bariatric surgical weight-loss center and underwent a sleeve gastrectomy. After reaching her new steady-state BMI of 36 eighteen months following her procedure, lymphoscintigraphy showed no improvement in lower extremity lymphatic function. Patients at risk for obesity-induced lymphedema should be counseled that they should seek weight-loss interventions before their BMI reaches 50, a threshold at which point lower extremity lymphedema may occur. Unlike other comorbidities that reverse following massive weight loss, obesity-induced lymphedema may not resolve.

Entities:  

Year:  2015        PMID: 26180727      PMCID: PMC4494496          DOI: 10.1097/GOX.0000000000000398

Source DB:  PubMed          Journal:  Plast Reconstr Surg Glob Open        ISSN: 2169-7574


Lymphedema is a disease caused by the anomalous development of the lymphatic system or injury to lymphatic vasculature. We previously reported that extreme obesity can cause lower extremity lymphedema (“obesity-induced lymphedema”)[1] and that a body mass index (BMI) threshold exists between 50 and 60 at which point lymphatic dysfunction occurs.[1,2] Although idiopathic and traumatic lymphedema are noncurable, it is unknown whether obesity-induced lymphedema improves following weight loss.

CASE REPORT

A 46-year-old woman presented to our Lymphedema Program complaining of bilateral lower extremity swelling. Her height and weight were 153 cm and 187 kg (BMI = 80). The patient reported that at age 34 she weighed 68 kg (BMI = 29), her legs were asymptomatic, and she subsequently began to steadily gain weight. Other than her obesity, she had no risk factors for lymphedema (eg, family history of lymphedema, primary lymphedema, travel to areas endemic for filariasis, and inguinal radiation/lymphadenectomy/operations). The patient’s lower extremity lymphatic function was evaluated by lymphoscintigraphy, which is 100% specific and 92% sensitive for lymphedema.[3] Lymphoscintigraphy at her initial presentation showed impaired lymphatic drainage of both lower extremities consistent with lymphedema (Fig. 1). She was referred to a bariatric surgical weight-loss center and underwent a sleeve gastrectomy. After reaching her new steady-state BMI of 36 eighteen months following her procedure, lymphoscintigraphy showed no improvement in lower extremity lymphatic function.
Fig. 1.

Obesity-induced lymphedema not improved following massive weight loss. A, Forty-six-year-old woman with a BMI of 71 before undergoing a weight-loss operation. Lymphoscintigram shows delayed transit of Tc-99m filtered sulfur colloid to the inguinal nodes 45 minutes following intradermal injection into the feet consistent with lymphatic dysfunction and lymphedema (*). Lymph nodes are visualized 2 hours following administration of radiolabeled tracer (^). B, Eighteen months following sleeve gastrectomy the patient’s BMI decreased to 36. Lymphoscintigram image of inguinal nodes at 45 minutes (*) and 120 minutes (^). Despite significant reduction in the size of her lower extremities, she continues to have delayed transit of radiolabeled tracer to her inguinal nodes and no improvement in her lymphatic function.

Obesity-induced lymphedema not improved following massive weight loss. A, Forty-six-year-old woman with a BMI of 71 before undergoing a weight-loss operation. Lymphoscintigram shows delayed transit of Tc-99m filtered sulfur colloid to the inguinal nodes 45 minutes following intradermal injection into the feet consistent with lymphatic dysfunction and lymphedema (*). Lymph nodes are visualized 2 hours following administration of radiolabeled tracer (^). B, Eighteen months following sleeve gastrectomy the patient’s BMI decreased to 36. Lymphoscintigram image of inguinal nodes at 45 minutes (*) and 120 minutes (^). Despite significant reduction in the size of her lower extremities, she continues to have delayed transit of radiolabeled tracer to her inguinal nodes and no improvement in her lymphatic function.

DISCUSSION

Lymphedema is a disease caused by the anomalous development of the lymphatic system or injury to lymphatic vasculature. The condition involves the extremities, although the genitalia can be affected as well. Lymphedema is progressive, and the area enlarges over time. Patients suffer from psychosocial morbidity, infection, difficulty using the extremity, and rarely malignant degeneration. This report documents the first patient with obesity-induced lower extremity lymphedema who had serial evaluation of lymphatic function before and after a surgical weight-loss procedure. The finding that lymphedema did not improve in this individual despite massive weight loss has broad implications. Obesity, which affects one-third of the US population, is an increasing public healthcare problem.[4] Patients at risk for obesity-induced lymphedema should be counseled that they need to seek weight-loss interventions before their BMI reaches 50, a threshold where irreversible lower extremity lymphedema may occur. Unlike other comorbidities that reverse following massive weight loss (eg, diabetes, hyperlipidemia, hypertension, and sleep apnea),[5] obesity-induced lymphedema may not resolve. As a result, after losing weight, obese patients may continue to suffer from a progressive, incurable condition over the course of their lives. The mechanism by which obesity causes lymphatic dysfunction is unclear. If obesity collapsed lymphatics or increased lymph production overloaded transport capacity, then lymphatic flow would be expected to improve following weight loss. Because lymphatic dysfunction remains despite massive weight loss, obesity likely damages lymphatic structures through inflammation and/or other mechanisms. Further study is necessary to determine if variables such as severity of obesity, duration of lymphatic dysfunction, and comorbidities affect the reversibility of obesity-induced lymphedema.

CONCLUSIONS

Obesity-induced lymphedema may develop once a patient's BMI exceeds 50. We report our first patient with obesity-induced lower extremity lymphedema who was followed prospectively before and after weight loss. Despite lowering her BMI from 80 to 36, her lymphatic function did not improve. Consequently, obesity-induced lymphedema may cause irreversible lymphatic dysfunction. Individuals at risk for the condition should be referred to a bariatric surgical weight loss center.
  5 in total

1.  Lower-extremity lymphedema and elevated body-mass index.

Authors:  Arin K Greene; Frederick D Grant; Sumner A Slavin
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  Obesity-induced lymphedema: clinical and lymphoscintigraphic features.

Authors:  Arin K Greene; Frederick D Grant; Sumner A Slavin; Reid A Maclellan
Journal:  Plast Reconstr Surg       Date:  2015-06       Impact factor: 4.730

Review 3.  Bariatric surgery for morbid obesity.

Authors:  Eric J DeMaria
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

4.  Prevalence and trends in obesity among US adults, 1999-2008.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Lester R Curtin
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272

5.  Noninvasive evaluation of the swollen extremity: experiences with 190 lymphoscintigraphic examinations.

Authors:  P Gloviczki; D Calcagno; A Schirger; P C Pairolero; K J Cherry; J W Hallett; H W Wahner
Journal:  J Vasc Surg       Date:  1989-05       Impact factor: 4.268

  5 in total
  7 in total

1.  Lymphovenous Anastomosis for Morbidly Obese Patients with Lymphedema.

Authors:  Shuhei Yoshida; Isao Koshima; Hirofumi Imai; Toshio Uchiki; Ayano Sasaki; Yumio Fujioka; Shogo Nagamatsu; Kazunori Yokota; Shuji Yamashita
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-05-27

Review 2.  Skin optical properties in the obese and their relation to body mass index: a review.

Authors:  Andres J Rodriguez; Mel Tananant Boonya-Ananta; Mariacarla Gonzalez; Vinh Nguyen Du Le; Jesse Fine; Cristina Palacios; Mike J McShane; Gerard L Coté; Jessica C Ramella-Roman
Journal:  J Biomed Opt       Date:  2022-03       Impact factor: 3.758

3.  Effects of weight reduction on the breast cancer-related lymphedema: A systematic review and meta-analysis.

Authors:  Chi-Lin Tsai; Wei-Wen Chang
Journal:  Breast       Date:  2020-05-28       Impact factor: 4.380

4.  High prevalence of musculoskeletal pain in individuals with severe obesity: sites, intensity, and associated factors.

Authors:  Carolina Rodrigues Mendonça; Matias Noll; Annelisa Silva E Alves de Carvalho Santos; Ana Paula Dos Santos Rodrigues; Erika Aparecida Silveira
Journal:  Korean J Pain       Date:  2020-07-01

Review 5.  Lymphatic Collecting Vessel: New Perspectives on Mechanisms of Contractile Regulation and Potential Lymphatic Contractile Pathways to Target in Obesity and Metabolic Diseases.

Authors:  Yang Lee; Scott D Zawieja; Mariappan Muthuchamy
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

6.  Lymphatic Valve Dysfunction in Western Diet-Fed Mice: New Insights Into Obesity-Induced Lymphedema.

Authors:  Jorge A Castorena-Gonzalez
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

7.  Gigantic Suprapubic Lymphedema: A Case Study.

Authors:  Roozbeh Tanhaeivash; Tobias Franiel; Marc-Oliver Grimm; Marcus Horstmann
Journal:  World J Mens Health       Date:  2016-08-23       Impact factor: 5.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.